Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review.

Yang, Dexiang; Dai, Ranran; Zhang, Qi; Fang, Ping

Yang, Dexiang; Dai, Ranran; Zhang, Qi; Fang, Ping.

Affiliation

Yang D; Department of Respiratory Diseases, People's Hospital of Tongling, Tongling, China.
Dai R; Department of Respiratory Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Zhang Q; Center for Cancer Research, National Cancer Institute, National Institutes of Health, USA.
Fang P; Department of Respiratory Diseases, People's Hospital of Tongling, Tongling, China.

Saudi J Biol Sci ; 25(5): 888-894, 2018 Jul.

Article in En | MEDLINE | ID: mdl-30108437

Key words

ALK, anaplastic lymphoma kinase; Adverse effect; Antiangiogenesis; CT, computed tomography; Clinical trial; EGFR, epidermal growth factor receptor; Efficacy; NSCLC; NSCLC, non-small cell lung cancer; OS, overall survival; PD, progression disease; PET, proton emission tomography; PFS, progression-free survival; PR, partial response; ROS1, ROS proto-oncogene 1; SD, stable disease; TKI, tyrosine kinase inhibitor; VEGF, vascular endothelial growth factor

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: Saudi J Biol Sci Year: 2018 Document type: Article Affiliation country: China Country of publication:

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google